HC Wainwright Reduces Earnings Estimates for UroGen Pharma

UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of UroGen Pharma in a research note issued on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.93) per share for the quarter, down from their prior estimate of ($0.83). HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.27) EPS and FY2026 earnings at $0.29 EPS.

A number of other equities analysts have also recently issued reports on URGN. D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $38.20.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $10.82 on Thursday. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70. The stock has a market cap of $253.77 million, a price-to-earnings ratio of -3.43 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a fifty day moving average of $10.45 and a 200-day moving average of $11.70.

Remove Ads

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million.

Insider Activity

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma during the fourth quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in shares of UroGen Pharma in the fourth quarter valued at approximately $67,000. Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma in the fourth quarter valued at approximately $101,000. BNP Paribas Financial Markets increased its position in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after purchasing an additional 5,890 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma during the 4th quarter valued at approximately $126,000. Institutional investors own 91.29% of the company's stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.